1-(4'-chlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 1-(4'-chlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride
• 英文别名: 1-(4-chlorophenyl)-2H-1,3,5-triazine-4,6-diamine;hydrochloride
• 化学式: C₉H₁₀ClN₅*ClH
• 分子量: 260.126
• InChiKey: UPFGKGUFISXWPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.17
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  80
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  二甲醇缩甲醛 、 1-(4-氯苯基)双胍盐酸盐 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 1-(4'-chlorophenyl)-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride
  参考文献：
  名称：

  Dihydrofolate reductase inhibitors

  摘要：

  化合物的化学式(I)或(II)，其中X为氢、卤素、烷基、芳基烷基、芳氧基、芳基烷氧基或烷氧基，Y为氢、卤素、烷基、芳基烷基、芳氧基、芳基烷氧基或烷氧基，或者化学式(a)中A和B不同，A和B中之一为CH2，另一个为O、NH或S，或者A和B都为CH2或CH═，而Ra、Rb和Rc相同或不同，分别为氢、卤素、烷基、烷氧基、芳氧基、芳基烷基或芳基烷氧基。R1为氢，R2为氢、C1-C6烷基或芳基，未被卤素、氰基、羟基、C1-C6烷基（未被卤素、氰基、羟基、C1-C6烷氧基、芳基烷基、芳氧基或芳基取代）取代或取代的烷基、芳基烷基、芳基烷氧基、芳氧基或芳基，未被卤素、氰基、羟基、C1-C6烷基或C1-C6烷氧基取代或取代的烷基、芳基烷基、芳基烷氧基、芳氧基或芳基；以及其药学上可接受的盐；但当R2为苯基且Y为氢时，X不为氯。

  公开号：

  US20030203908A1

文献信息

• Development of a Lead Inhibitor for the A16V+S108T Mutant of Dihydrofolate Reductase from the Cycloguanil-Resistant Strain (T9/94) of <i>Plasmodium falciparum</i>^†
  作者：Yongyuth Yuthavong、Tirayut Vilaivan、Netnapa Chareonsethakul、Sumalee Kamchonwongpaisan、Worachart Sirawaraporn、Rachel Quarrell、Gordon Lowe

  DOI：10.1021/jm0009181

  日期：2000.7.1

  The Ala16Val+Ser108Thr (A16V+S108T) mutant of the Plasmodium falciparum dihydrofolate reductase (DHFR) is a key mutant responsible for cycloguanil-resistant malaria due to steric interaction between Val-16 and one of the C-2 methyl groups of cycloguanil. 4,6-Diamino-1,2-dihydrotriazines have been prepared, in which both methyl groups of cycloguanil are replaced by H or by H and an alkyl or phenyl group, and their inhibition constants against wild-type and mutant DHFR determined. The S108T mutation is considered to decrease cycloguanil binding further through the effect on the orientation of the p-chlorophenyl group. By moving the p-chloro-substituent to the m-position in the chlorophenyl group, the activity against the A16V+S108T mutant enzyme is improved, and this effect is reinforced by the p-chloro substituent in the 3,4-dichlorophenyl group. A lead compound has been found with inhibitory activity similar to that of cycloguanil against the wild-type DHFR and about 120-fold more effective than cycloguanil against the A16V+S108T mutant enzyme. The activity of this compound against P. falciparum clone (T9/94 RC17) which harbors the A16V+S108T DHFR is about 85-fold greater than cycloguanil.
• 1-Aryl-4,6-diamino-1,2-dihydrotriazine as antimalarial agent: a new synthetic route
  作者：M. Kidwai、P. Mothsra、R. Mohan、S. Biswas

  DOI：10.1016/j.bmcl.2004.12.049

  日期：2005.2

  Some novel derivatives of 1-aryl-4,6-diamino-1,2-dihydrotriazines have been synthesized using neat technology under microwaves. These were tested in vitro against both sensitive and resistant Plasmodium falciparum strains for antimalarial activity. (C) 2004 Elsevier Ltd. All rights reserved.
• [EN] DIHYDROFOLATE REDUCTASE INHIBITORS<br/>[FR] INHIBITEURS DE LA DIHYDROFOLATE REDUCTASE
  申请人：ISIS INNOVATION

  公开号：WO2001053276A1

  公开（公告）日：2001-07-26

  A compound of formula (I) or (II), wherein X is hydrogen, halogen, alkyl, aralkyl,aryloxy, arylalkoxy or alkoxy, Y is hydrogen, halogen, alkyl, aralkyl, aryloxy, arylalkoxy or alkoxy, or formula (a) wherein A and B are different and one of A and B is CH2 and the other is O, NH, or S or A and B are both CH2 or CH=, and R?a, Rb, and Rc¿ are the same or different and are hydrogen, halogen, alkyl, alkoxy, aryloxy, aralkyl or arylalkoxy. R1 is hydrogen, and R2 is hydrogen, C¿1?-C6 alkyl or aryl which is unsubstituted or substituted by halogen, cyano, hydroxy, C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano, hydroxy, C1-C6 alkoxy, aralkyl, aryloxy or aryl, C1-C6 alkoxy, aralkyl, arylalkoxy, aryloxy or aryl, which is unsubstituted or substituted by halogen, cyano, hydroxy, C1-C6 alkyl or C1-C6 alkoxy; and pharmaceutically acceptable salts thereof; with the proviso that when R?2¿ is phenyl and Y is hydrogen, X is not chlorine.
• Dihydrofolate reductase inhibitors
  申请人：——

  公开号：US20030203908A1

  公开（公告）日：2003-10-30

  A compound of formula (I) or (II), wherein X is hydrogen, halogen, alkyl, aralkyl,aryloxy, arylalkoxy or alkoxy, Y is hydrogen, halogen, alkyl, aralkyl, aryloxy, arylalkoxy or alkoxy, or formula (a) wherein A and B are different and one of A and B is CH 2 and the other is O, NH, or S or A and B are both CH 2 or CH═, and R a , R b , and R c are the same or different and are hydrogen, halogen, alkyl, alkoxy, aryloxy, aralkyl or arylalkoxy. R 1 is hydrogen, and R 2 is hydrogen, C 1 -C 6 alkyl or aryl which is unsubstituted or substituted by halogen, cyano, hydroxy, C 1 -C 6 alkyl, which is unsubstituted or substituted by halogen, cyano, hydroxy, C 1 -C 6 alkoxy, aralkyl, aryloxy or aryl, C 1 -C 6 alkoxy, aralkyl, arylalkoxy, aryloxy or aryl, which is unsubstituted or substituted by halogen, cyano, hydroxy, C 1 -C 6 alkyl or C 1 -C 6 alkoxy; and pharmaceutically acceptable salts thereof; with the proviso that when R 2 is phenyl and Y is hydrogen, X is not chlorine. 1

  化合物的化学式(I)或(II)，其中X为氢、卤素、烷基、芳基烷基、芳氧基、芳基烷氧基或烷氧基，Y为氢、卤素、烷基、芳基烷基、芳氧基、芳基烷氧基或烷氧基，或者化学式(a)中A和B不同，A和B中之一为CH2，另一个为O、NH或S，或者A和B都为CH2或CH═，而Ra、Rb和Rc相同或不同，分别为氢、卤素、烷基、烷氧基、芳氧基、芳基烷基或芳基烷氧基。R1为氢，R2为氢、C1-C6烷基或芳基，未被卤素、氰基、羟基、C1-C6烷基（未被卤素、氰基、羟基、C1-C6烷氧基、芳基烷基、芳氧基或芳基取代）取代或取代的烷基、芳基烷基、芳基烷氧基、芳氧基或芳基，未被卤素、氰基、羟基、C1-C6烷基或C1-C6烷氧基取代或取代的烷基、芳基烷基、芳基烷氧基、芳氧基或芳基；以及其药学上可接受的盐；但当R2为苯基且Y为氢时，X不为氯。